We believe that only research-based compounds with well defined mechanisms of action should be considered when targeting cellular metabolism. In our development process each compound is evaluated on the basis of quality of synthesis, safety, pharmacokinetics and clinical efficacy. All development steps are carried out according to the highest recognized international standards within the pharmaceutical industry (GLP, GMP, GCP).

Our basic premise is that by correcting metabolic dysfunctions (i.e. underlying deficiencies in the metabolic coenzymes and cofactors) which cause chronic diseases and aging, the progression of the damage associated with metabolic compromise and related toxicity pathways can be slowed down or corrected. We focus not only on developing products but also on developing supplements  and a greater understanding of the diseases related to abnormalities in metabolism, with special attention to mitochondrial function.

To this end, we are researching metabolic compounds, alone and in specific combinations, each individually selected based on its particular biochemical and physiological properties, to develop a synergistic formulations that target specific conditions.

Some of the compounds being studied include:

• L-carnitine, Acetyl-L-carnitine, Propionyl-L-carnitine, and their analogs

• coenzyme Q10

• omega-3 fatty acids (EPA, DHA)

• amino acids

• minerals

• nicotinamide

• riboflavin

• pantothenic acid

• folic acid

• vitamin E

• others 

A very strict scientific rationale is used in developing evidence-based formulations.